Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 72

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 72
---
 ended December 31,                                              
                                                        2024                                                                         
                                                        $                                                                            
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                                                                                                            
  Active ingredients                                                                         2,394      1,213      1,181         97  
  Pharmaceutical                                                                               928          -        928        100  
  Total revenue                                                                              3,322      1,213      2,109        174  
  Cost of sales                                                                                                                      
  Active ingredients                                                                         1,200      1,066        134         13  
  Pharmaceutical                                                                                73          -         73        100  
  Total cost of sales                                                                        1,273      1,066        207         19  
  Gross Margin                                                                               2,049        147      1,902      1,294  
  Gross Margin %                                                                                62         12                        

Our
total revenue for the three-month period ended December 31, 2024, was $3.3 million as compared to $1.2 million for the same period in
2023, an increase of $2.1 million. This increase was primarily due to a $1.2 million increase in sales of Avenanthramides, Beta Glucan
and Oat Oil from prior period, as well as a $0.9 million in Macrilen revenue due to the acquisition of Aeterna as described in the plan
of arrangement section above. Cost of sales for the three-month period ended December 31, 2024, increased by $0.2 million, primarily
due to the higher sales volumes during the period. The gross margin for the three-month period ended December 31, 2024, was $2.0 million
as compared to $0.1 million for the same period in 2023, an increase of $1.9 million. This increase is in line with the movements in
revenue and cost of sales and is primarily due to the high gross margin on pharmaceutical sales.

  (in thousands of US dollars, except percentages)      Year ended December 31,                                            
                                                        2024                                                               
                                                        $                                                                  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                                                                                                  
  Active ingredients                                                                 8,492      7,143      1,349       19  
  Pharmaceutical                                                                     1,